UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.
| Last Trade: | US$43.06 |
| Daily Change: | 1.15 2.74 |
| Daily Volume: | 317,118 |
| Market Cap: | US$2.950B |
February 27, 2025 February 25, 2025 February 18, 2025 February 13, 2025 February 05, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
